Edge-to-Edge Repair Reduces Hospitalization and Mortality Rates in Secondary Mitral Valve Regurgitation?

Severe secondary mitral valve regurgitation is associated to hospitalization and mortality. 

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

The COAPT study has shown the superiority of guideline directed medical therapy at maximal tolerated doses according to guidelines (GDMT) plus edge-to-edge transcatheter repair (TEER) versus GMDT alone.

However, at present there is no information on the impact of hospitalizations and their relationship to all-cause or cardiovascular mortality. 

The COAPT study was analyzed, including 614 patients: 302 receiving GDMT + TEER and 312 GDMT alone. 

This analysis included hospitalization for any cause (ACH), hospitalization for cardiovascular cause (CCH), hospitalization for cardiac failure (CFH), non-cardiovascular related hospitalization (NCCH), and all-cause mortality.

436 patients (71%) had been hospitalized at least once at 2-year followup. 

Read also: BEST-CLI: Revascularization of Critical Lower Limb Ischemia, a Pragmatic Study.

Mean age was 74, 35% were women. There were no differences in diabetes, hypertension, COPD, PCI, CABG, and peripheral vascular disease. Hospitalized patients showed higher rates of kidney failure, atrial fibrillation, STS score, and higher BNP, in addition to worse 6-minute walk test performance and worse quality of life.  The echo-Doppler prior randomization showed more severe tricuspid failure and higher right ventricular systolic pressure. 

There was no difference between patients receiving GMDT + TEER o GMDT alone between randomization and first hospitalization. Mean time was 253 days.

After 2 years, patients receiving GDMT + TEER presented lower ACH, CCH and CFH globally, both fatal and non-fatal, with no difference in NCCH or hospitalization not related to cardiac failure. 

In addition, those receiving the device lived 2 months longer and outside the hospital. 

Read also: Sex Differences According to Thrombus Burden in STEMI Patients.

Mortality was associated to hospitalization, growing significantly as the number of hospitalizations increased. 

At multivariable analysis, GMDT + TEER was associated with significantly lower all-cause and cardiovascular mortality and hospitalization for cardiac failure. 

Conclusion

The COAPT looked at patients with heart failure and severe secondary mitral valve regurgitation receiving GDMT + TEER, presenting at 2 years fewer fatal hospitalizations, fewer hospitalizations for cardiac failure, and longer survival outside the hospital vs. patients receiving GDMT alone. Hospitalization for cardiac failure was strongly associated with mortality, regardless the treatment.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure The COAPT Trial.

Reference: Gennaro Giustino, et al. J Am Coll Cardiol 2022;80:1857–1868.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

FRANCE TAVI Registry: Coronary Adverse Events After TAVI

Between 30% and 70% of patients undergoing transcatheter aortic valve implantation (TAVI) have coronary artery disease (CAD). However, the prognostic impact of CAD in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...